Epstein-Barr Virus and Mononucleosis

• Viral entry and B-cell transformation: EBV binds to CD21 (complement receptor 2) on the surface of B lymphocytes via its gp350 envelope glycoprotein, facilitating viral entry and delivery of the viral genome into the nucleus. Following entry, the virus expresses latency-associated antigens (LANAs) including EBNA1-6 (Epstein-Barr nuclear antigens) and LMPs (latent membrane proteins 1-3), which immortalize B cells by disrupting normal cell-cycle checkpoint control. Specifically, EBNA2 and EBNA3 proteins inactivate the p53 tumor suppressor and Rb pathway, while LMP1 provides constitutive signaling analogous to CD40 activation, driving B-cell proliferation and survival. This transformation occurs without viral replication in latently infected cells, establishing the foundation for lifelong persistence. During acute infection, a massive expansion of polyclonal B cells occurs, driven both by direct viral transformation and by robust CD8+ cytotoxic T-cell (CTL) responses. The polyclonal B-cell activation explains the transient production of nonspecific autoantibodies (heterophile antibodies, rheumatoid factor, anti-nuclear antibodies) characteristic of acute EBV infection.

• Immune response and clinical manifestations: The clinical syndrome of IM is paradoxically driven not primarily by direct viral cytopathic effects but by the host's vigorous adaptive immune response attempting to control viral replication and transformed B cells. CD8+ T cells specific for viral antigens (particularly those targeting EBNA and LMP epitopes) expand dramatically, comprising up to 40% of circulating lymphocytes during acute infection; these activated T cells infiltrate tissues including the pharynx (causing pharyngitis and exudate), spleen (causing splenic enlargement and risk of rupture), liver (causing hepatitis), and lymph nodes (causing lymphadenopathy). The production of inflammatory cytokines including IFN-γ, TNF-α, and IL-6 by activated T cells and macrophages mediates systemic symptoms including fever, malaise, and myalgias. Atypical lymphocytes (activated T cells) observed on peripheral blood smear represent these EBV-specific CTLs; their presence correlates with disease severity. The exudative pharyngitis and soft palate petechiae result from intensive lymphocytic infiltration and inflammation of Waldeyer's ring structures.

• Splenic involvement and risk of rupture: EBV demonstrates remarkable tropism for splenic B cells and T cells, causing dramatic splenic enlargement (splenomegaly occurs in 50-60% of clinically apparent IM cases) due to both B-cell hyperplasia and extensive T-cell infiltration. The spleen becomes friable and congested, with disrupted normal splenic architecture; the capsule stretches to accommodate massive organ enlargement, creating conditions predisposing to spontaneous or minor trauma-induced rupture. Splenic rupture, occurring in approximately 0.1-0.5% of IM cases, represents a surgical emergency as the spleen ruptures along the hilum, causing life-threatening hemorrhage. The pathophysiological basis for rupture involves both the mechanical stress of extreme enlargement and the immunological process of destroying infected cells.

• Liver involvement and hepatocellular injury: Hepatic involvement in EBV infection occurs through two mechanisms: direct infection of hepatocytes and infiltration of portal tracts and sinusoids by activated T lymphocytes. EBV-specific CTLs recognize infected hepatocytes and mediate hepatocellular apoptosis, resulting in mild to moderate elevations in transaminases (ALT and AST typically 3-10 times the upper limit of normal). Unlike acute viral hepatitis from hepatotropic viruses (HAV, HBV, HCV), EBV-associated hepatitis rarely causes fulminant hepatic failure in immunocompetent individuals, though hepatic dysfunction can be more severe in the immunocompromised.

• Lymphoid tissue response: Profound lymphoid hyperplasia occurs throughout the body in response to EBV antigen presentation and T-cell activation. In Waldeyer's ring, massive lymphoid hyperplasia causes pharyngeal edema, exudation, and potential airway obstruction—a feared complication in severe IM. Cervical, axillary, and inguinal lymph nodes enlarge as germinal centers expand and become filled with activated lymphocytes. The lymph node architecture shows preserved histology (distinguishing from lymphoma) with reactive follicular hyperplasia.

• Heterophile antibody production and cross-reactivity: During acute EBV infection, B cells produce heterophile antibodies—naturally occurring immunoglobulins that react with antigens structurally unrelated to EBV. The mechanisms underlying heterophile antibody production remain incompletely understood but may involve polyclonal B-cell activation and molecular mimicry. Notably, EBV-infected patients produce sheep red blood cell (SRBC) agglutinating antibodies detected by the Paul-Bunnell test and its modern variant the monospot test, which detects EBV-induced heterophile IgM antibodies that cross-react with Paul-Bunnell antigen present on sheep erythrocytes and beef red blood cells. This antibody response provides the basis for rapid diagnostic testing.

• Primary EBV infection: The fundamental etiology of infectious mononucleosis is primary (acute) infection with human herpesvirus 4 (EBV), transmitted through respiratory secretions, saliva, and potentially other body fluids. The virus demonstrates endemicity worldwide with universal or near-universal seroprevalence by adulthood. In developed nations with delayed exposure (socioeconomic factors, reduced crowding), primary infection more commonly occurs in adolescence and young adulthood, presenting with symptomatic IM. In developing countries and lower socioeconomic settings, primary infection typically occurs in early childhood, frequently presenting with asymptomatic or minimally symptomatic disease. The incubation period averages 4-6 weeks (range 2-8 weeks), during which viral replication occurs in nasopharyngeal epithelial cells before systemic dissemination.

• Age and socioeconomic status as risk modifiers: While EBV infection eventually affects nearly all humans, the age at primary infection critically determines clinical presentation severity. Infants and young children experiencing primary EBV infection typically manifest subclinical or mild upper respiratory tract infection. By contrast, adolescents and young adults (peak incidence 15-24 years) commonly develop symptomatic IM with full disease manifestations. This age-related shift toward clinical severity reflects developmental changes in immune responsiveness and the magnitude of CTL response. Epidemiologic data demonstrate that IM presenting with classic clinical syndrome occurs most frequently in this adolescent/young adult population in developed nations. Socioeconomic factors influence exposure timing: crowded living conditions and poor sanitation lead to earlier, often asymptomatic primary infection, while improved hygiene delays exposure to older ages when clinical disease becomes more apparent.

• Immunologic factors and prior exposure: Individuals seronegative for EBV (approximately 5-10% of adults) remain at risk for primary infection throughout life. Conversely, prior EBV infection confers robust protective immunity through both humoral (neutralizing antibodies against gp350 and other envelope glycoproteins) and cellular mechanisms (EBV-specific CTLs and memory responses). The seropositive state provides effective sterilizing immunity against reinfection. However, latent EBV persists lifelong in memory B cells, and viral reactivation occurs in approximately 1-2% of seropositive individuals, typically manifesting with subclinical viral shedding; clinical disease from reactivation is uncommon in immunocompetent hosts.

• Immunosuppression and reactivation disease: Immunocompromised individuals including those with HIV/AIDS (particularly CD4+ counts <50 cells/μL), solid organ or hematopoietic stem cell transplant recipients, and patients on long-term corticosteroids face increased risk for EBV reactivation producing oropharyngeal shedding and sometimes clinical disease. Reactivation disease in the severely immunocompromised can manifest as oral hairy leukoplakia (OHL), a white nonremovable plaque on the lateral tongue representing epithelial EBV replication, or rarely as EBV-associated post-transplant lymphoproliferative disorder (PTLD), a spectrum of EBV-driven B-cell proliferations ranging from benign polyclonal hyperplasia to frank lymphoma.

• Sex and hormonal factors: Interestingly, women of reproductive age may experience more symptomatic and severe IM compared to age-matched males, possibly reflecting hormonal influences on immune responsiveness, though this remains incompletely characterized. No clear male predominance or female predominance is established for primary infection.

• Fever and constitutional symptoms: Fever is nearly universal in symptomatic IM, typically presenting as high spiking fever (often 38.5-40°C/101-104°F) with a characteristically quotidian or double quotidian pattern (daily or twice-daily temperature spikes). Fever results from the massive inflammatory cytokine production by activated immune cells combating viral replication. Associated constitutional symptoms include severe malaise, profound fatigue often persisting weeks beyond acute illness, myalgias (muscle pain) reflecting systemic inflammation, headaches (sometimes severe), and chills. The severity of malaise is often remarkable—patients may be bedbound for several days at disease peak. This constellation of constitutional symptoms reflects the immunologic nature of IM and distinguishes it from typical bacterial pharyngitis.

• Pharyngitis and oropharyngeal findings: Pharyngeal pain is cardinal, often severe and occasionally causing dysphagia. The characteristic finding is exudative pharyngitis with gray-white or yellowish-white exudate coating the tonsils and posterior pharynx, mimicking streptococcal pharyngitis and frequently prompting inappropriate antibiotic therapy. Unlike streptococcal exudate which is typically thin and easily wiped away, the EBV exudate tends to be thick, adherent, and can be hemorrhagic. Additionally, soft palate petechiae (small red pinpoint hemorrhages) appear on the soft palate, hard palate, and uvula—a relatively specific finding for EBV IM, though not universally present. Pharyngeal edema may be severe enough to approach airway obstruction, particularly in cases receiving corticosteroids (which can paradoxically worsen airway obstruction by reducing immune-mediated inflammation too rapidly). Uvular edema and erythema contribute to the sore throat.

• Lymphadenopathy: Cervical lymphadenopathy occurs in 80-90% of symptomatic IM cases and is often dramatic, with lymph nodes enlarging to 2-3 cm or larger. The lymphadenopathy is typically symmetric, tender, and firm and may be accompanied by supraclavicular and axillary lymphadenopathy. Unlike bacterial lymphadenitis which is often unilateral and accompanied by overlying erythema, EBV-associated lymphadenopathy is characteristically generalized and non-suppurative. The tenderness reflects rapid lymph node enlargement and inflammatory infiltration. In some cases, marked cervical lymphadenopathy combined with pharyngeal edema can create a "bull neck" appearance.

• Splenomegaly: Splenic enlargement occurs in 50-60% of cases and is typically asymptomatic, detected on abdominal palpation as a spleen edge palpable below the left costal margin. Splenic enlargement is maximal around day 10-14 of illness. Patients with splenomegaly must receive counseling regarding splenic rupture risk and activity restriction; splenic rupture, though rare, represents a life-threatening complication occurring from minor trauma or rarely spontaneously. Splenomegaly usually resolves by 6-12 weeks, though residual enlargement can persist for months.

• Hepatomegaly: Liver enlargement is present in 10-15% of cases, typically mild, and usually asymptomatic. Hepatic involvement is reflected in laboratory abnormalities more commonly than in clinical hepatomegaly; approximately 80% of IM patients show elevated transaminases despite clinical absence of hepatomegaly.

• Rash: A maculopapular rash appears in 5-15% of cases presenting as small red macules and papules, typically beginning on the trunk and spreading peripherally. The rash is characteristically pruritic, nonblanching, and non-vesicular. Critically, if patients with EBV IM receive ampicillin or amoxicillin (common when IM is misdiagnosed as streptococcal pharyngitis), nearly 90-100% develop an intense maculopapular rash within 5-7 days of antibiotic initiation. This ampicillin rash is NOT a true allergy but rather a specific reaction to the combination of ampicillin and EBV infection; the mechanism remains incompletely understood but may involve immune complex deposition or direct drug interaction with EBV antigens. Patients with ampicillin rash from EBV can later tolerate beta-lactams without difficulty.

• Atypical presentation variants: Some patients present with atypical symptoms or atypical organ involvement. CNS involvement occurs in <1% of cases, manifesting as aseptic meningitis (lymphocytic pleocytosis on CSF analysis), encephalitis (altered mental status, seizures), or Guillain-Barré syndrome (ascending paralysis from immune-mediated demyelination). Myocarditis with ventricular dysfunction, pericarditis, and arrhythmias can occur. Hemolytic anemia results from IgG autoantibodies against red blood cell antigens, producing positive direct antiglobulin test (DAT/Coombs test). Thrombocytopenia and neutropenia reflect immune destruction of platelets and granulocytes. Interstitial pneumonia and pulmonary infiltrates occur rarely.

• Fulminant IM and hyperinflammatory states: Though uncommon in immunocompetent individuals, severe hyperinflammatory IM can develop with massive hepatosplenomegaly, profound thrombocytopenia, hemolytic anemia, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and multi-organ failure—a syndrome sometimes termed fulminant infectious mononucleosis. This occurs more frequently in immunocompromised populations and in the rare setting of X-linked lymphoproliferative disease (XLP), an inherited disorder impairing EBV-specific CTL responses.

• Clinical history and exposure: Eliciting a history of recent contact with ill persons, kissing or close oral contact, symptoms of upper respiratory infection in contacts, and symptom duration of 1-3 weeks supports IM diagnosis. Importantly, absence of sick contacts does not exclude EBV infection, as many adults shed virus asymptomatically.

• Atypical lymphocytes on peripheral blood smear: The hallmark peripheral blood finding is atypical lymphocytes (also termed Downey cells), which are activated CD8+ T lymphocytes representing the immune response to EBV antigen.

Immediate stabilization (rare but decisive)

• Splenic rupture: hypotension, left upper quadrant/left shoulder pain (Kehr sign), peritonitis. Large-bore IV access, crystalloid and blood products, emergent surgical consultation per ATLS principles. Hemodynamically stable patients with a contained subcapsular or low-grade injury are frequently managed nonoperatively — bed rest, serial hemoglobin, and close hemodynamic monitoring in a center with immediate operative capability (Eastern Association for the Surgery of Trauma blunt splenic injury guidance); persistent instability or ongoing bleeding prompts angioembolization or splenectomy. If splenectomy is performed, arrange vaccination against encapsulated organisms — pneumococcal, meningococcal, and Haemophilus influenzae type b — per CDC/ACIP asplenia recommendations.
• Impending airway obstruction from tonsillar and Waldeyer's ring hyperplasia: stridor, drooling, inability to lie flat. Secure the airway with ENT/anesthesia present; systemic corticosteroids (e.g., dexamethasone) are the accepted exception to the no-steroid rule, with tonsillectomy reserved for refractory obstruction.

First-line therapy — supportive only

• Rest, oral hydration, and analgesia/antipyresis: acetaminophen or an NSAID (ibuprofen). The AAP Red Book and CDC state there is no specific therapy for infectious mononucleosis; disease is self-limited and driven by the host CTL response, not by ongoing lytic replication.
• Activity restriction: avoid contact/collision sports and heavy lifting for at least the first several weeks of illness while splenomegaly persists. AAP and American Medical Society for Sports Medicine guidance places return to contact sport at roughly four weeks from symptom onset, individualized; routine serial ultrasound is not required because spleen size poorly predicts rupture.

What not to do

• Aminopenicillins: ampicillin/amoxicillin precipitate a florid morbilliform rash in EBV infection. If group A strep is confirmed by RADT/culture, the IDSA pharyngitis guideline supports penicillin V or amoxicillin — but in suspected mononucleosis choose penicillin V or a first-generation cephalosporin (cephalexin) instead.
• Antivirals: acyclovir and valacyclovir reduce oropharyngeal viral shedding but do not shorten symptoms; not recommended.
• Routine corticosteroids: not indicated for uncomplicated fever or sore throat. Reserve for airway compromise, severe autoimmune cytopenias, myocarditis, or CNS disease.
• Aspirin in children: avoid because of Reye syndrome risk.

Escalation — separate the two lymphoproliferative emergencies

• Severe immune thrombocytopenia or autoimmune hemolytic anemia: corticosteroids ± IVIG.
• PTLD: reduce immunosuppression and give rituximab (anti-CD20) ± chemotherapy, with transplant/hematology input; follow serial EBV DNA PCR.
• EBV-driven HLH: a rapidly fatal hyperinflammatory state requiring urgent etoposide-based immunochemotherapy (Histiocyte Society HLH-94/HLH-2004: etoposide plus dexamethasone, ± cyclosporine, with intrathecal therapy for CNS disease); rituximab is an adjunct to lower the EBV-infected B-cell burden, and allogeneic HSCT is pursued for familial disease or X-linked lymphoproliferative disease. "Reduction of immunosuppression" does not apply to primary or immunocompetent-host HLH.

Emergencies

• Splenic rupture (emergency): the capsule stretches over a friable, lymphocyte-infiltrated spleen, so minor trauma — or occasionally no identifiable trauma — produces a capsular tear with subcapsular hematoma or free intraperitoneal hemorrhage. Signals: sudden LUQ pain, referred left shoulder pain (Kehr sign), tachycardia, hypotension. Peak risk coincides with maximal splenomegaly in the second week.
• Upper airway obstruction (emergency): massive tonsillar and adenoidal lymphoid hyperplasia. Signals: stridor, drooling, tripod posture, hypoxemia — more common in young children.
• EBV-driven hemophagocytic lymphohistiocytosis / fulminant IM (emergency): unchecked CTL and macrophage activation, classically in X-linked lymphoproliferative disease (SAP/SH2D1A mutation). Signals: persistent fever, cytopenias in ≥2 lines, markedly elevated ferritin and triglycerides, low fibrinogen, hemophagocytosis on marrow.

Hematologic

• Autoimmune hemolytic anemia: polyclonal B-cell activation generates antierythrocyte antibodies; anemia with elevated LDH and indirect bilirubin and low haptoglobin. The classically tested EBV association is cold agglutinin–mediated hemolysis from IgM with anti-i specificity, in which the direct antiglobulin test is positive for complement (C3d) rather than IgG; warm IgG-mediated hemolysis with an IgG-positive DAT is described but reported less often.
• Immune thrombocytopenia and neutropenia: antibody-mediated peripheral destruction; mucosal bleeding or unexplained fever with low counts.

Organ-specific

• Hepatitis: CTL killing of infected hepatocytes; transaminase elevation in most patients, jaundice uncommon, fulminant failure rare in immunocompetent hosts.
• Neurologic: aseptic meningitis, encephalitis, Guillain–Barré syndrome, Bell palsy, transverse myelitis, and the Alice in Wonderland syndrome (metamorphopsia) — CSF lymphocytic pleocytosis.
• Myocarditis/pericarditis: troponin rise, new heart failure or arrhythmia.

Late and treatment-related

• EBV-associated malignancy: Burkitt lymphoma (t(8;14), starry-sky), nasopharyngeal carcinoma, Hodgkin lymphoma, primary CNS lymphoma in AIDS, and post-transplant lymphoproliferative disorder after reduction of T-cell surveillance — signalled by rising EBV DNA PCR and new adenopathy or mass.
• Ampicillin/amoxicillin rash: not IgE-mediated; do not label the patient penicillin-allergic.
• Corticosteroid harms: hyperglycemia and possible masking of superinfection — another reason routine use is discouraged.
• Prolonged fatigue: may persist months after resolution of the acute illness.

• Triad plus fatigue: fever, exudative pharyngitis, posterior cervical lymphadenopathy in a teenager or young adult — the kissing disease. Posterior (not just anterior) cervical nodes and profound fatigue are the discriminators from streptococcal pharyngitis.
• Single best next step in a classic stem: heterophile antibody (Monospot) test plus CBC with differential looking for >10% atypical lymphocytes (Downey cells) — activated CD8+ T cells, not infected B cells.
• The heterophile trap: the test is falsely negative in the first week of illness and in children under about age 4. If suspicion remains high, order EBV-specific serology (VCA IgM) or repeat testing — do not conclude "not EBV."
• Serology logic: VCA IgM = acute; VCA IgG without EBNA IgG = recent/acute; EBNA IgG appears weeks to months after onset, so its presence effectively excludes acute primary infection.
• The one association examiners love: ampicillin/amoxicillin → diffuse morbilliform rash in EBV. It is not a true penicillin allergy, and the patient may receive beta-lactams later.
• Counselling point tested as management: avoid contact sports and heavy lifting for several weeks (AAP/AMSSM guidance) because of splenic rupture risk; sudden LUQ pain with Kehr sign and hypotension is a surgical emergency.
• Receptor and oncology link: EBV enters B cells via gp350 binding CD21 (CR2) — the same receptor used by C3d. Downstream associations: Burkitt lymphoma (starry-sky, t(8;14) c-myc), nasopharyngeal carcinoma (Southern Chinese adults), Hodgkin lymphoma, CNS lymphoma in AIDS, PTLD, and oral hairy leukoplakia (non-scrapable lateral tongue plaque).
• Common distractors: heterophile-negative mononucleosis suggests CMV (less pharyngitis/adenopathy), acute HIV (order HIV RNA, not just antibody), or toxoplasmosis. Steroids and acyclovir are attractive but wrong answers in uncomplicated disease.